EP1417329A1 - Procedes de production de microbes resistant aux antibiotiques et nouveaux antibiotiques - Google Patents

Procedes de production de microbes resistant aux antibiotiques et nouveaux antibiotiques

Info

Publication number
EP1417329A1
EP1417329A1 EP01963754A EP01963754A EP1417329A1 EP 1417329 A1 EP1417329 A1 EP 1417329A1 EP 01963754 A EP01963754 A EP 01963754A EP 01963754 A EP01963754 A EP 01963754A EP 1417329 A1 EP1417329 A1 EP 1417329A1
Authority
EP
European Patent Office
Prior art keywords
bacterium
antibiotic
gene
mismatch repair
bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01963754A
Other languages
German (de)
English (en)
Other versions
EP1417329A4 (fr
Inventor
Nicholas C. Nicolaides
Philip M. Sass
Luigi Grasso
J. Bradford Kline
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphotek Inc
Original Assignee
Morphotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek Inc filed Critical Morphotek Inc
Publication of EP1417329A1 publication Critical patent/EP1417329A1/fr
Publication of EP1417329A4 publication Critical patent/EP1417329A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C12Q1/20—Testing for antimicrobial activity of a material using multifield media

Definitions

  • This invention relates to the field of antimicrobial treatments and gene targets for the discovery of antimicrobial agents. In particular, it relates to the discovery of genes essential for growth and virulence of bacteria.
  • One approach for generating new therapies and/or therapeutic strategies against AR microbes is to develop methods that can generate a wide array of genomic alterations in a microbe's genome that can yield maximal number altered target genes that are capable of eliciting antibiotic resistance.
  • Once an AR strain is developed it can be used for rapid genome analysis to identify mutant gene(s) that are capable of rendering a microbe resistant to an antibiotic for target identification.
  • Such analysis can involve any of a variety of methods used by those skilled in the art for identifying mutations and/or differential gene expression, including but not limited to differential gene expression using microarrays, cDNA subtraction, differential protein analysis, complementation assays, single nucleotide polymorphosm (SNP) analysis or whole genome sequencing to identify altered loci.
  • SNP single nucleotide polymorphosm
  • a bottleneck to generating genetically diverse microbes is the inability to generate nonbiased genome- wide mutations.
  • Many mutagenesis methods are available whereby the use of chemical and radiation exposure has been successful in generating genomic mutations.
  • a limitation of this approach is that these various methods are usually DNA site specific or are extremely toxic, therefore limiting the mutation spectra and the opportunity to identify a maximal number of genes, when mutated, that are able to confer resistance to an antibiotic.
  • Recently, work done by Nicolaides, et al. (Nicolaides et al. (1998) Mol. Cell. Biol. 18:1635- 1641; U.S. patent 6,146,894) has demonstrated the utility of introducing dominant negative mismatch repair mutants into cells to confer global DNA hypermutability.
  • mutations are in the form of point mutations or small insertion-deletions that are distributed equally throughout the genome.
  • MMR mismatch repair
  • the ability to manipulate the mismatch repair (MMR) process of a target host organism can lead to an increase in the mutability of the target host genome, leading to the generation of innovative cell subtypes with varying phenotypes from the original wild-type cells.
  • Variants can be placed under a specified, desired selective process the result of which is the capacity to select for a novel organism that expresses an altered biological molecule(s) and has a new phenotype.
  • the invention provides new uses of MMR deficiency in bacteria to identify antibiotic resistance (AR) genes and pathways that can lead to the generation of novel therapeutic strategies for alternative clinical strategies.
  • AR antibiotic resistance
  • Antibiotic resistant (AR) microbes express a number of genes that are essential for growth of the organism in an infection, and serve as useful reagents for target discovery and/or screening lines for the discovery of novel antimicrobial agents.
  • This invention provides an approach to the identification of genes that confer anti-microbial resistance, and the use of those genes, and bacterial strains expressing mutant forms of genes, in the identification, characterization, and evaluation of targets for therapeutic development.
  • this application teaches of the use of employing structural information of the gene, gene product and mutant strains in screening for antimicrobial agents active against the genes and their corresponding products and pathways. Positive compounds can then be used as final products or precursors to be further developed into antibacterial agents.
  • This invention also provides methods of treating microbial infections in mammals by administering an antimicrobial agent active against such an identified target gene or product, and the pharmaceutical compositions effective for such treatment.
  • the invention provides methods of decreasing MMR activity of a microbial host to produce AR strains. Using this process, commercially viable microbes that are resistant to a wide range of antibiotics can be directly selected for the resistance to an anti-microbial agent of interest. AR microbes may be genetically screened to identify novel therapeutic targets for drug develoment. Once a bacterium with a specified resistance is isolated, the MMR activity may be restored by several methods well known to those skilled in the art as a means to gentically "fix" the new mutations in the host genome, thereby making the AR microbe suitable for comparative molecular analysis to the wild-type strain as well as for drug screening to identify novel antimicrobial compounds.
  • the endogenous repair activity can be restored if the gene is expressed by an inducible promoter system, including but not limited to promoters such as: TAC-LACI, tryp (Brosius et al. (1984) Gene 27:161- 172), araBAD (Guzman et al. (1995) J. Bact. 177:4121-4130) pLex (La Vallie et al. (1992) Bio.Technology 11:187-193), pRSET (Schoepfer, R (1993) Gene 124:83-85), pT7 (Shadier (1991) J. Mol.
  • promoters such as: TAC-LACI, tryp (Brosius et al. (1984) Gene 27:161- 172), araBAD (Guzman et al. (1995) J. Bact. 177:4121-4130) pLex (La Vallie et al. (1992) Bio.Technology 11:187-193),
  • the invention provides methods for generating antibiotic resistant bacteria comprising the steps of: blocking mismatch repair in the bacterium whereby the bacterium becomes hypermutable; contacting the bacterium with at least one antibiotic determining whether the bacterium is resistant to the antibiotic, thereby generating antibiotic resistant bacteria.
  • mismatch repair may be blocked in some embodiments by introducing a polynucleotide encoding a wild-type allele of a mismatch repair gene into a cell, whereby the wild-type allele inactivates the endogenous MMR activity by binding to and interfering with the resident activity.
  • the cell becomes hypermutable as a result of the introduction of the gene.
  • a polynucleotide encoding a dominant negative allele of a mismatch repair gene is introduced into a cell, where the dominant negative gene is derived from a mismatch repair gene from a different organism.
  • the cell becomes hypermutable as a result of the introduction of the gene.
  • MMR activity is inhibited for ten rounds of cell division and then the MMR activity is restored therefore restoring the genetic stability.
  • An example of a dominant negative MMR gene is the PMS2-134 gene.
  • a polynucleotide encoding an allele of a mismatch repair gene is introduced into a bacterial cell, where the mismatch repair gene is derived from a wild-type or altered mammalian, yeast, fungal, amphibian, insect, plant or bacterial mismatch repair gene.
  • the cell becomes hypermutable as a result of the introduction of the gene.
  • mismatch repair may be blocked by introducing an antisense nucleic acid molecule into the bacterium wherein the antisense nucleic acid molecule specifically binds to a mismatch repair gene and inhibits mismatch repair in the bacterium.
  • methods are provided for generating a genetic alteration of a bacterial host genome to produce variant strains expressing new output traits.
  • Transgenic bacterium comprising a polynucleotide encoding a wild-type allele of a mismatch repair gene is grown.
  • the bacteria are comprised of a set of altered genes for a desired biological phenotype.
  • methods are provided for generating a genetic alteration of a bacterial host genome to produce variant strains that are resistant to antimicrobial agents.
  • Bacteria with decreased mismatch repair are grown.
  • the bacteria are comprised of a set of altered genes for a desired antibiotic-resistance phenotype.
  • methods are provided for creating a hypermutable bacterium using a wild-type MMR allele for antibiotic-resistance selection, and restoring genomic stability of a selected host by inactivating or decreasing the expression of the wild-type MMR allele.
  • a method for creating a hypermutable bacteria using a dominant negative MMR allele for antibiotic-resistance selection, and restoring genomic stability of a selected host by inactivating or decreasing the expression of the dominant negative MMR gene allele.
  • a method for creating a hypermutable bacteria expressing an antisense gene to a MMR gene for antibiotic-resistance selection, and restoring genomic stability of a selected host by inactivating or decreasing the expression of the dominant negative MMR gene allele.
  • a method for creating a hypermutable bacteria using chemical inhibitors of MMR for antibiotic-resistance selection, and restoring genomic stability of a selected host by removing the chemical inhibitor, by introducing a dominant negative allele of a mismatch repair gene into the bacterium.
  • the dominant negative allele may be, for example, a PMS2- 134 gene.
  • mismatch repair may be blocked by exposing the bacterium a to a compound that inhibits mismatch repair whereby cells are grown in the presence of the compound and undergo multiple rounds of cell divison in the absence of MMR, yielding sibs that are genetically diverse. Sibs are then selected for antibiotic resistance. AR strains are removed from chemical inhibitor and the endogenous MMR activity is restored leaving genetically stable strains that are now suitable for gene discovery and/or therapeutic agent development.
  • the compound that blocks mismatch repair may be an anthracene derivative, including, but not limited 1,2-dimethylanthracene, 9,10-dimethyl anthracene, 7,8- dimethylanthracene, 9,10-diphenylanthracene, 9,10-dihydroxymethylanthracene, 9- hydroxymethyl- 10-methylanthracene, dimethylanthracene- 1 ,2-diol, 9-hydroxymethyl- 10- methylanthracene-l,2-diol, 9-hydroxymethyl- 10-methylanthracene-3,4-diol, 9, 10-di-m- toly anthracene.
  • the compound that blocks MMR activity is an ATP analog.
  • the compound that blocks MMR activity is a nuclease inhibitor.
  • the compound that blocks MMR activity is a DNA polymerase inhibitor.
  • the methods of the invention may further comprise exposing the bacteria to chemical mutagens. While it has been documented that MMR deficiency can lead to as much as a 1000- fold increase in the endogenous DNA mutation rate of a host, there is no assurance that MMR deficiency alone will be sufficient to alter every gene within the DNA of the host bacterium to create altered biochemicals with new activity(s).
  • DNA mutagens include ionizing radiation and UV-irradiation, which are known to cause DNA mutagenesis in bacteria can also be used to potentially enhance this process.
  • ionizing radiation and UV-irradiation which are known to cause DNA mutagenesis in bacteria can also be used to potentially enhance this process.
  • These agents which are extremely toxic to host cells and, therefore, result in a decrease in the actual pool size of altered bacterial cells, are more tolerated in MMR defective hosts and in turn allow for a enriched spectrum and degree of genomic mutation ( Drummond et al. (1996) J. Biol. Chem. 271:9645-19648).
  • the methods of the invention may be used to generate AR bacteria which are resistant to such antibiotic compounds as, for example, quinilones, aminoglycosides, magainins, defensins, tetracyclines, beta-lactams, macrolides, lincosamide, sulfonamides, chloramphenicols, nitrofurantoins, and isoniazids.
  • antibiotic compounds for example, quinilones, aminoglycosides, magainins, defensins, tetracyclines, beta-lactams, macrolides, lincosamide, sulfonamides, chloramphenicols, nitrofurantoins, and isoniazids.
  • the step of determining whether the bacterium is resistant to an antibiotic may comprise analyzing the bacterium for multiantiboitic resistance.
  • the methods of the invention may comprise making antibiotic resistant bacteria genetically stable, such as by removing the MMR inhibitory molecule, for example.
  • the genome of the antibiotic resistant bacterium and the genome of a wild-type strain of the bacterium may be compared by sequence analysis of the entire genomes, or compared by microarray analysis, for example.
  • the genome of said antibiotic resistant bacterium and the genome of said wild-type strain of said bacterium are compared by: introducing gene fragments from the antibiotic resistant bacterium into the wild-type bacterium, thereby producing mutant bacteria; selecting a mutant bacterium with antibiotic resistance; and sequencing the gene fragment from the mutant bacterium with antibiotic resistance, thereby identifying the antibiotic resistant gene.
  • the invention also provides methods of using microbial strains that are naturally defective for MMR due to defects in genes encoding for MMR proteins. Strains in which mutS, mutL, mutH, or mutY genes are defective have been reported to be defective in MMR activity (Modrich (1994) Science 266: 1959-1960).
  • the methods of the invention may employ bacterial strains with mutant endogenous MMR genes for selecting for variants that are AR. Once an AR variant strain is identified, the genetic stability of the microbe can be restored by expressing a functional gene that can complement the defective MMR gene activity.
  • Mutant strains can be used for gene identification by isolating DNA fragments derived from the MMR defective antibiotic-resistant strains. These bacteria contain DNA fragments with altered sequences that can be introduced into wild-type counterparts (antibiotic susceptible) and screened for fragments that confer antibiotic resistance. Conversely, DNA fragments derived from the wild-type bacteria can be introduced into mutant bacterial strains to screen for genes effective via loss-of-function mutated genes. The fact that a clone is complemented suggests the introduced fragment contains a gene encoding for an antibiotic- resistant gene product. Other methods can also be used to identify AR genes including but not limited to microarray analysis of gene expression, differential expression and/or differential protein analysis know by those skilled in the art.
  • the microbial strains described herein have either been generated and characterized in a manner which essentially provides a process by which the manipulation of MMR can confer AR against a wide range of anti-microbial compounds and that these strains are now useful for target discovery and/or therapeutic agent discovery as screening lines.
  • methods of producing a stable bacterium expressing a new phenotype is provided. Turning off the expression of the MMR- wild-type alleles, MMR-dominant negative alleles, or MMR-antisense alleles, results in genetically stable bacteria expressing a new output trait(s).
  • the invention also provides antibiotic resistant strains of bacteria produced by the methods of the invention.
  • Figure 1 shows growth of tetracyclin-resistant mutant bacteria carrying a dominant negative allele of PMS2 in the pT7Ea plasmid (134/V5), tetracyclin-resistant mutant bacteria carrying a the PMSR3 gene in the pT7Ea plasmid (R3), and wild-type bacteria carrying the empty pT7Ea plasmid (T7), on medium containing tetracyclin at 0, 4 and 6 hours after tetracycline addition.
  • the inventors present a method for developing hypermutable bacteria by altering the activity of endogenous mismatch repair (MMR) activity of hosts to generate antibiotic resistant (AR) microbes for target discovery and the development of novel anti-microbial agent by screening for new compounds.
  • MMR endogenous mismatch repair
  • AR antibiotic resistant
  • Wild-type and some dominant negative alleles of mismatch repair genes when introduced and expressed in bacteria, increase the rate of spontaneous mutations by reducing the effectiveness of the endogenous MMR-mediated DNA repair activity, thereby rendering the bacteria highly susceptible to genetic alterations due to hypermutabihty.
  • Hypermutable bacteria can then be utilized to screen for novel mutations in a gene or a set of genes that produce variant siblings exhibiting new output traits not found in the wild-type cells such as antibiotic resistance.
  • mismatch repair also called mismatch proofreading
  • mismatch proofreading is an evolutionarily highly conserved process that is carried out by protein complexes described in cells as disparate as prokaryotic cells such as bacteria to more complex mammalian cells (Modrich (1994) Science 266:1959-1960; Strand et al. (1993) Nature 365:274-276; Su et al. (1988) J. Biol. Chem. 263:6829-6835; Aronshtam.and Marinus (1996) Nucl. Acids Res. 24:2498-2504; Wu and Marinus (1994) J. Bacteriol. 176:5393-400).
  • a mismatch repair gene is a gene that encodes one of the proteins of such a mismatch repair complex.
  • a mismatch repair complex is believed to detect distortions of the DNA helix resulting from non-complementary pairing of nucleotide bases.
  • the non-complementary base on the newer DNA strand is excised, and the excised base is replaced with the appropriate base that is complementary to the older DNA strand.
  • cells eliminate many mutations that occur as a result of mistakes in DNA replication, resulting in genetic stability of the sibling cells derived from the parental cell.
  • Some wild-type MMR gene alleles as well as dominant negative alleles cause a mismatch repair defective phenotype even in the presence of a wild-type MMR gene allele in the same cell.
  • An example of a dominant negative allele of a MMR gene is the human gene hPMS2-134, which carries a truncation mutation at codon 134 (Nicolaides et al. (1998) Mol. Cell. Biol. 18:1635-1641). The mutation causes the product of this gene to abnormally terminate at the position of the 134th amino acid, resulting in a shortened polypeptide containing the N-terminal 133 amino acids. Such a mutation causes an increase in the rate of mutations, which accumulate in cells after DNA replication.
  • Dominant negative alleles of a mismatch repair gene can be obtained from the cells of humans, animals, yeast, bacteria, plants or other organisms. Screening cells for defective mismatch repair activity can identify such alleles. Mismatch repair genes may be mutant or wild-type. Bacterial host MMR may be mutated or not. The term bacteria used in this application include any organism from the prokaryotic kingdom.
  • These organisms include genera such as but not limited to Agrobacterium, Anaerobacter, Aquabacterium, Azorhizobium, Bacillus, Bradyrhizobium, Cryobacterium, Escherichia, Enterococcus, Heliobacterium, Klebsiella, Lactobacillus, Methanococcus, Methanothermobacter, Micrococcus, Mycobacterium, Oceanomonas, Pseudomonas, Rhizobium, Staphylococcus, Streptococcus, Streptomyces, Thermusaquaticus, Thermaerobacter, Thermobacillus, etc. Other procaryotes that can be used for this application are listed at
  • telomeres can be analyzed for variations from the wild-type sequence.
  • Dominant negative alleles of a mismatch repair gene can also be created artificially, for example, by producing variants of the hPMS2-134 allele or other mismatch repair genes (Nicolaides et al. (1998) Mol. Cell. Biol. 18:1635-1641).
  • Various techniques of site-directed mutagenesis can be used.
  • the suitability of such alleles, whether natural or artificial, for use in generating hypermutable bacteria can be evaluated by testing the mismatch repair activity (using methods described in Nicolaides et al. (1998) Mol. Cell. Biol. 18:1635- 1641) caused by the allele in the presence of one or more wild-type alleles, to determine if it is a dominant negative allele.
  • a bacterium that over-expresses a wild-type mismatch repair allele or a dominant negative allele of a mismatch repair gene will become hypermutable. This means that the spontaneous mutation rate of such bacteria is elevated compared to bacteria without such alleles.
  • the degree of elevation of the spontaneous mutation rate can be at least 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, 200-fold, 500-fold, or 1000-fold that of the normal bacteria as measured as a function of bacterial doubling/minute.
  • a polynucleotide encoding either a wild-type or a dominant negative form of a mismatch repair protein is introduced into bacteria.
  • the gene can be any dominant negative allele encoding a protein which is part of a mismatch repair complex, for example, mutS, mutL, mutH, or mutY homologs of the bacterial, yeast, plant or mammalian genes (Modrich (1994) Science 266:1959-1960; Prolla et al. (1994) Science 264:1091-1093).
  • the dominant negative allele can be naturally occurring or made in the laboratory.
  • the polynucleotide can be in the form of genomic DNA, cDNA, RNA, or a chemically synthesized polynucleotide or polypeptide.
  • the molecule can be introduced into the cell by transfection or other methods well described in the literature.
  • Transfection is any process whereby a polynucleotide or polypeptide is introduced into a cell.
  • the process of transfection can be carried out in a bacterial culture using a suspension culture.
  • the bacteria can be any type classified under the prokaryotes.
  • transfection will be carried out using a suspension of cells but other methods can also be employed as long as a sufficient fraction of the treated cells incorporate the polynucleotide or polypeptide so as to allow transfected cells to be grown and utilized.
  • the protein product of the polynucleotide may be transiently or stably expressed in the cell.
  • Techniques for transfection are well known to those skilled in the art. Available techniques to introduce a polynucleotide or polypeptide into a prokaryote include but are not limited to electroporation, transduction, cell fusion, the use of chemically competent cells (e.g., calcium chloride), and packaging of the polynucleotide together with lipid for fusion with the cells of interest.
  • the cell can be propagated and manipulated in either liquid culture or on a solid agar matrix, such as a petri dish. If the transfected cell is stable, the gene will be retained and expressed at a consistent level when the promoter is constitutively active, or when in the presence of appropriate inducer molecules when the promoter is inducible, for many cell generations, and a stable, hypermutable bacterial strain results.
  • An isolated bacterial cell is a clone obtained from a pool of a bacterial culture by chemically selecting out strains using antibiotic selection of an expression vector. If the bacterial cell is derived from a single cell, it is defined as a clone.
  • Bacterial cultures may be screened for antibiotic resistance against a wide array of antibiotic compounds.
  • bacteria produced by the methods of the invention may be screened for resistance to quinilones, aminoglycosides, magainins, defensins, tetracyclines, beta-lactams, macrolides, lincosamide, sulfonamides, chloramphenicols, nitrofurantoins, and isoniazids.
  • the antibiotics may be incorporated into solid or liquid growth medium, for example.
  • a polynucleotide encoding an inhibitory form of a mismatch repair protein can be introduced into the genome of a bacterium or propagated on an extra-chromosomal plasmid. Selection of clones harboring the mismatch repair gene expression vector can be accomplished by addition of any of several different antibiotics, including but not limited to ampicillin, kanamycin, chloramphenicol, zeocin, and tetracycline.
  • the microbe can be any species for which suitable techniques are available to produce transgenic microorganisms, such as but not limited to genera including Bacillus, Pseudomonas, Staphylococcus, Escherichia and others.
  • transgenic bacteria Any method for making transgenic bacteria known in the art can be used.
  • the polynucleotide is transfected into the microbe by one of the methods well known to those in the art.
  • the microbial culture is grown under conditions that select for cells in which the polynucleotide encoding the mismatch repair gene is either incorporated into the host genome as a stable entity or propagated on a self-replicating extra-chromosomal plasmid, and the protein encoded by the polynucleotide fragment transcribed and subsequently translated into a functional protein within the cell.
  • a transgenic microbe is engineered to harbor the expression construct, it is then propagated to generate and sustain a culture of transgenic microbes indefinitely.
  • transgenic microorganism Once a stable, transgenic microorganism has been engineered to express a functional MMR protein, the microbe can be exploited to create novel mutations in one or more target gene(s) of interest harbored within the same microorganism.
  • a gene of interest can be any gene naturally possessed by the bacterium or one introduced into the bacterial host by standard recombinant DNA techniques.
  • the target gene(s) may be known prior to the selection or unknown.
  • One advantage of employing such transgenic microbes to induce mutations in resident or extra-chromosomal genes within the microbe is that it is unnecessary to expose the microorganism to mutagenic insult, whether it be chemical or radiation in nature, to produce a series of random gene alterations in the target gene(s).
  • Mutations can be detected by analyzing the recombinant microbe for alterations in the genotype and/or phenotype post-activation of the decreased mismatch repair activity of the transgenic microorganism.
  • Novel genes that produce altered phenotypes in MMR-defective microbial cells can be discerned by any variety of molecular techniques well known to those in the art.
  • the microbial genome can be isolated and a library of restriction fragments cloned into a plasmid vector.
  • the library can be introduced into a "normal" cell and the cells exhibiting the novel phenotype screened. Transformed cells are then screened for the new phenotype (e.g., antibiotic resistance).
  • a plasmid is isolated from those normal, transformed cells that exhibit the novel phenotype and the inserted gene(s) characterized by DNA sequence analysis.
  • differential messenger RNA screen can be employed utilizing driver and tester RNA (derived from wild-type and novel mutant respectively) followed by cloning the differential transcripts and characterizing them by standard molecular biology methods well known to those skilled in the art.
  • driver and tester RNA derived from wild-type and novel mutant respectively
  • cloning the differential transcripts and characterizing them by standard molecular biology methods well known to those skilled in the art.
  • the mutant sought is on encoded by an extrachromosmal plasmid, then following co-expression of the dominant negative MMR gene and the gene of interest to be altered and phenotypic selection, the plasmid is isolated from mutant clones and analyzed by DNA sequence analysis by methods well known to those in the art.
  • the screening of cells may be performed by microarray analysis.
  • microarray analysis microchips containing all or a subset of all expressed bacterial genes may be screened using RNA molecules derived from the wild-type or antibiotic resistant strain whereby RNA derived from one strain is reverse transcribed using FluoroLink Cy3 and the other RNA sample is reverse transcribe-labelled using Cy5 dUTP. Labelled cDNAs from each organism are used to probe the microchip whereby unique message from one source will generate a distinct signal while message expressed from both sources will generate a common fluorescence.
  • microchips containing olignucleotide derived from the wild-type strain can be used to hybridize genomic fragments from the antibiotic resistant strain to identify fragments containing a mutated gene by loss of hybridization.
  • Phenotypic screening for output traits in MMR-defective mutants can be by biochemical activity and/or a physical phenotype of the altered gene product.
  • a mutant phenotype can also be detected by identifying alterations in electrophoretic mobility, DNA binding in the case of transcription factors, spectroscopic properties such as IR, CD, X-ray crystallography or high field NMR analysis, or other physical or structural characteristics of a protein encoded by a mutant gene. It is also possible to screen for altered novel function of a protein in situ, in isolated form, or in model systems.
  • One can screen for alteration of any property of the microorganism associated with the function of the gene of interest, whether the gene is known prior to the selection or unknown. The aforementioned screening and selection discussion is meant to illustrate the potential means of obtaining novel mutants with commercially valuable output traits.
  • Plasmid expression vectors that harbor the mismatch repair (MMR) gene inserts can be used in combination with a number of commercially available regulatory sequences to control both the temporal and quantitative biochemical expression level of the dominant negative MMR protein.
  • the regulatory sequences can be comprised of a promoter, enhancer or promoter/enhancer combination and can be inserted either upstream or downstream of the MMR gene to control the expression level.
  • the regulatory promoter sequence can be any of those well known to those in the art, including but not limited to the lad, tetracycline, tryptophan-inducible, phosphate inducible, T7-polymerase-inducible (Studier et al. (1991) J. Mol. Biol.
  • the activity of the aberrant MMR activity is attenuated or eliminated by any of a variety of methods, including removal of the inducer from the culture medium that is responsible for promoter activation, gene disruption of the aberrant MMR gene constructs, electroporation and or chemical curing of the expression plasmids (Brosius(1988) Biotechnology 10:205-225; Wang et al. (1999) J. ofFujian Agricultural University 28:43-46; Fu et. al. (1988) Chem. Abstracts 34:415-418).
  • the expression of the dominant negative MMR gene will be turned on to select for hypermutable microbes with new output traits.
  • the expression of the dominant negative dominant negative MMR allele is rapidly turned off to reconstitute a genetically stable strain that produces a new output trait of commercial interest.
  • the resulting microbe is now useful as a stable strain that can be applied to various commercial applications, depending upon the selection process placed upon it.
  • transgenic constructs will be used that express wild-type mismatch repair genes sufficient to complement the genetic defect and therefore restore mismatch repair activity of the host after trait selection (Grzesiuk et al. (1988) Mutagenesis 13:127-132; Bridges et al. (1997) EMBOJ. 16:3349-3356; LeClerc (1996) Science 15:1208- 1211; Jaworski, A. et al. (1995) Proc. Nat/. Acad. Sci USA 92:11019-11023).
  • the resulting microbe is genetically stable and can be applied to various commercial practices.
  • Genomics 30: 195-206 the related PMS134 truncated MMR gene (Nicolaides et ⁇ /.(1998) Mol. Cell. Biol. 18:1635-1641); the plant mismatch repair genes (derived from Arabidopsis thaliana), ATPMS2 (SEQ ID NO:30), At PMSl (SEQ ID NO:32), and MutS homolog (SEQ ID NO:34) and those genes that are homologous to the 134 N-terminal amino acids of the PMS2 gene which include the MutL family of MMR proteins and including the PMSR and PMS2L homologs described by Hori et al.
  • the corresponding polypeptide sequences for the above-referenced nucleic acid sequences are as follows: yeast MLH1 (SEQ ID NO:2); mouse PMS2 (SEQ ID NO:4); human PMS2 (SEQ ID NO:6); human PMSl (SEQ ID NO:8); human MSH2 (SEQ ID NO: 10); human MLH1 (SEQ ID NO: 12); PMS2-134 (SEQ ID NO: 14); human MSH6 (SEQ ID NO: 16); human PMSR2 (SEQ ID NO: 18); human PMSR3 (SEQ ID NO:20); human PMSL9 (SEQ ID NO:22); human MLH3 (SEQ ID NO:29); ATPMS2 (SEQ ID NO:31); ATPMS1 (SEQ ID NO:
  • the invention provides the use of DNA mutagens in combination with MMR defective microbial hosts to enhance the hypermutable production of genetic alterations. This has not been demonstrated in the art previously as a means to accentuate MMR activity for generation of microorganisms with clinically relevant output traits such as antibiotic resistance.
  • the bacteria cells are rendered hypermutable by introducing a chemical inhibitor of mismatch repair into the growth medium.
  • Chemical inhibitors of mismatch repair that may be used to generate hypermutable bacterial cells include anthracene-derived compounds comprising the formula:
  • the anthracene has the formula:
  • R ⁇ -R 10 are independently hydrogen, hydroxyl, amino, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S- alkenyl, N-alkenyl,O-alkynyl, S-alkynyl, N-alkynyl, aryl, substituted aryl, aryloxy, substituted aryloxy, heteroaryl, substituted heteroaryl, aralkyloxy, arylalkyl, alkylaryl, alkylaryloxy, arylsulfonyl, alkylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, guanidino, carboxy, an alcohol, an amino acid, sulfonate, alkyl sulfonate, CN, NO 2 , an aldehyde group
  • alkyl refers to a hydrocarbon containing from 1 to about 20 carbon atoms. Alkyl groups may straight, branched, cyclic, or combinations thereof. Alkyl groups thus include, by way of illustration only, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cyclohexylmethyl, and the like. Also included within the definition of "alkyl” are fused and/or polycyclic aliphatic cyclic ring systems such as, for example, adamantane.
  • alkenyl denotes an alkyl group having at least one carbon-carbon double bond.
  • alkynyl denotes an alkyl group having at least one carbon-carbon triple bond.
  • anthracene has the formula:
  • R ⁇ -R 10 are independently hydrogen, hydroxyl, amino, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S- alkenyl, N-alkenyl,O-alkynyl, S-alkynyl, N-alkynyl, aryl, substituted aryl, aryloxy, substituted aryloxy, heteroaryl, substituted heteroaryl, aralkyloxy, arylalkyl, alkylaryl, alkylaryloxy, arylsulfonyl, alkylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, guanidino, carboxy, an alcohol, an amino acid, sulfonate, alkyl sulfonate, CN, NO , an aldehyde group,
  • alkyl refers to a hydrocarbon containing from 1 to about 20 carbon atoms. Alkyl groups may straight, branched, cyclic, or combinations thereof. Alkyl groups thus include, by way of illustration only, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cyclohexylmethyl, and the like. Also included within the definition of "alkyl” are fused and/or polycyclic aliphatic cyclic ring systems such as, for example, adamantane. As used herein the term “alkenyl” denotes an alkyl group having at least one carbon-carbon double bond. As used herein the term “alkynyl” denotes an alkyl group having at least one carbon-carbon triple bond.
  • the anthracene has the formula:
  • Ri-Rio are independently hydrogen, hydroxyl, amino, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S- alkenyl, N-alkenyl,O-alkynyl, S-alkynyl, N-alkynyl, aryl, substituted aryl, aryloxy, substituted aryloxy, heteroaryl, substituted heteroaryl, aralkyloxy, arylalkyl, alkylaryl, alkylaryloxy, arylsulfonyl, alkylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, guanidino, carboxy, an alcohol, an amino acid, sulfonate, alkyl sulfonate, CN, NO 2 , an aldehyde group
  • anthracenes include, but are not limited to 1,2-dimethylanthracene, 9,10-dimethyl anthracene, 7,8-dimethylanthracene, 9,10-diphenylanthracene, 9,10- dihydroxymethylanthracene, 9-hydroxymethyl- 10-methylanthracene, dimethylanthracene- 1 ,2- diol, 9-hydroxymethyl- 10-methylanthracene- 1 ,2-diol, 9-hydroxymethyl- 10-methylanthracene- 3,4-diol, and 9, 10-di-m-tolyanthracene.
  • anthracene refers to the compound anthracene.
  • anthracene refers to the compound anthracene.
  • anthracene refers to the compound anthracene.
  • anthracene refers to the compound anthracene.
  • the alkyl, alkenyl, alkynyl, aryl, aryloxy, and heteroaryl substituent groups described above may bear one or more further substituent groups; that is, they may be "substituted".
  • these substituent groups can include halogens (for example fluorine, chlorine, bromine and iodine), CN, NO , lower alkyl groups, aryl groups, heteroaryl groups, aralkyl groups, aralkyloxy groups, guanidino, alkoxycarbonyl, alkoxy, hydroxy, carboxy and amino groups.
  • substituted alkyl groups include, for example, alkyl groups fluoro-, chloro-, bromo- and iodoalkyl groups, aminoalkyl groups, and hydroxyalkyl groups, such as hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, and the like. In some preferred embodiments such hydroxyalkyl groups contain from 1 to about 20 carbons.
  • aryl means a group having 5 to about 20 carbon atoms and which contains at least one aromatic ring, such as phenyl, biphenyl and naphthyl. Preferred aryl groups include unsubstituted or substituted phenyl and naphthyl groups.
  • aryloxy denotes an aryl group that is bound through an oxygen atom, for example a phenoxy group.
  • hetero denotes the presence of at least one hetero (i.e., non- carbon) atom, which is in some preferred embodiments independently one to three O, N, S, P, Si or metal atoms.
  • heteroaryl denotes an aryl group in which one or more ring carbon atom is replaced by such a heteroatom.
  • Preferred heteroaryl groups include pyridyl, pyrimidyl, pyrrolyl, furyl, thienyl, and imidazolyl groups.
  • aralkyl (or “arylalkyl”) is intended to denote a group having from 6 to 15 carbons, consisting of an alkyl group that bears an aryl group.
  • aralkyl groups include benzyl, phenethyl, benzhydryl and naphthylmethyl groups.
  • alkylaryl (or “alkaryl”) is intended to denote a group having from 6 to 15 carbons, consisting of an aryl group that bears an alkyl group.
  • aralkyl groups include methylphenyl, ethylphenyl and methylnaphthyl groups.
  • arylsulfonyl denotes an aryl group attached through a sulfonyl group, for example phenylsulfonyl.
  • alkylsulfonyl denotes an alkyl group attached through a sulfonyl group, for example methylsulfonyl.
  • arylalkyloxy or “aralkyloxy” are equivalent, and denote a group of formula -O-R'-R ⁇ , where R ; is R is alkyl, alkenyl, or alkynyl which can be optionally substituted as described herein, and wherein R denotes a aryl or substituted aryl group.
  • alkylaryloxy or “alkaryloxy” are equivalent, and denote a group of formula -O-R / -R // , where R 7 is an aryl or substituted aryl group, and R is alkyl, alkenyl, or alkynyl which can be optionally substituted as described herein.
  • cyclic ether has its usual meaning of a cyclic ether containing several oxygen atoms.
  • organosulfur compound denotes aliphatic or aromatic sulfur containing compounds, for example thiols and disulfides.
  • organometallic group denotes an organic molecule containing at least one metal atom.
  • organosilicon compound denotes aliphatic or aromatic silicon containing compounds, for example alkyl and aryl silanes.
  • carboxylic acid denotes a moiety having a carboxyl group, other than an amino acid.
  • amino acid denotes a molecule containing both an amino group and a carboxyl group.
  • the amino acids are -, ⁇ -, 7- or ⁇ -amino acids, including their stereoisomers and racemates.
  • L- amino acid denotes an ⁇ -amino acid having the L configuration around the ⁇ -carbon, that is, a carboxylic acid of general formula CH(COOH)(NH 2 )-(side chain), having the L- configuration.
  • D-amino acid similarly denotes a carboxylic acid of general formula CH(COOH)(NH )-(side chain), having the D-configuration around the ⁇ -carbon.
  • Non-naturally occurring (i.e., unnatural) amino acid side chains are moieties that are used in place of naturally occurring amino acid side chains in, for example, amino acid analogs. See, for example, Lehninger, Biochemistry, Second Edition, Worth Publishers, Inc, 1975, pages 72-77, incorporated herein by reference.
  • Amino acid substituents may be attached through their carbonyl groups through the oxygen or carbonyl carbon thereof, or through their amino groups, or through functionalities residing on their side chain portions.
  • the cells are made hypermutable using ATP analogs capable of blocking ATPase activity required for MMR.
  • MMR reporter cells are screened with ATP compound libraries to identify those compounds capable of blocking MMR in vivo.
  • ATP analogs that are useful in blocking MMR activity include, but are not limited to, nonhydrolyzable forms of ATP such as AMP-PNP and ATP[gamma]S block the MMR activity (Galio, L. et al. (1999) Nucl. Acids Res. 27:2325- 2331; Allen, D.J. et al. (1997) EMBOJ. 16:4467-4476; Bjornson K.P. et al. (2000) Biochem. 39:3176-3183).
  • the ATPase inhibitors inhibit MMR and the cells become hypermutable as a result.
  • the cells are made hypermutable using nuclease inhibitors that are able to block the exonuclease activity of the MMR biochemical pathway.
  • MMR reporter cells are screened with nuclease inhibitor compound libraries to identify compounds capable of blocking MMR in vivo.
  • nuclease inhibitors that are useful in blocking MMR activity include, but are not limited to analogs of N-Ethylmaleimide, an endonuclease inhibitor (Huang, Y.C., et.al. (1995) Arch. Biochem. Biophys.
  • the cells are made hypermutable using DNA polymerase inhibitors that are able to block the polymerization required for mismatch-mediated repair.
  • MMR reporter cells are screened with DNA polymerase inhibitor compound libraries to identify those compounds capable of blocking MMR in vivo.
  • DNA polymerase inhibitors that are useful in blocking MMR activity include, but are not limited to, analogs of actinomycin D (Martin, S.J., et.al. (1990) J. Immunol. 145:1859), Aphidicolin (Kuwakado, K. et.al. (1993) Biochem. Pharmacol.
  • Bacterial cells rendered hypermutable using chemical inhibitors of MMR may be made genetically stable when the desired phenotype is obtained by removing the MMR inhibitory molecule.
  • the bacterial cells are made hypermutable by introducing plamids that generate antisense messages wherein the antisense RNA specifically bind to MMR genes and prevent efficient expression of MMR proteins.
  • the antisense transcripts are at least 12 nucleotides in length and, more preferably are at least 20, 30, 40, 50 nucleotides or more in length.
  • the antisense transcripts specifically bind to regions of the MMR gene to inhibit expression.
  • the antisense transcripts specifically bind to regulatory regions of the MMR gene such as to the MMR promoter region, Kozak consensus sequences, and the like.
  • polystyrene endonucleic acid strands forming complementary base pairing in Watson-Crick arrangement, allowing for mismatches such that 100% complementarity is not required. In general, the complementarity will be about 85%, 90%, 95% or more.
  • Plasmids that may be used to express an antisense MMR transcript include any vector generally known in the art to express antisense transcripts, such as for example, those found in Qian Y. et al. (1998) Mutat. Res. 418(2-3):61-71.
  • Example 1 Generation of MMR defective bacteria.
  • Bacterial expression constructs were prepared using the human PMS2 related gene (hPMSR3) (Nicolaides et al. (1995) Genomics 30:195-206) and the human PMS134 cDNA (Nicolaides et al. (1998) Mol. Cell. Biol. 18: 1635-1641), both of which are capable of inactivating MMR activity and thereby increase the overall frequency of genomic hypermutation.
  • hPMSR3 human PMS2 related gene
  • human PMS134 cDNA Nicolaides et al. (1998) Mol. Cell. Biol. 18: 1635-1641
  • the use of regulatable expression vectors will allow for suppression of dominant negative MMR alleles and restoration of the MMR pathway and genetic stability in hosts cells (Brosius, J. (1988) Biotechnology 10:205-225).
  • PCR polymerase chain reaction
  • the 5' oligonucleotide has the following sequence: 5'-acg cat atg gag cga get gag age teg agt-3' (SEQ ID NO:23)that includes the Ndel restriction site (cat atg).
  • the 3'- oligonucleotide has the following sequence: 5 '-gaa ttc tta tea cgt aga ate gag ace gag gag agg gtt agg gat agg ctt ace agt tec aac ctt cgc cga tgc-3' (SEQ ID NO:24) that includes an EcoRI site (gaattc) and the 14 amino acid epitope for the V5 antibody.
  • the oligonucleotides were used for PCR under standard conditions that included 25 cycles of PCR (95°C for 1 minute, 55°C for 1 minute, 72°C for 1.5 minutes for 25 cycles followed by 3 minutes at 72°C).
  • the PCR fragment was purified by gel electrophoresis and cloned into pTA2.1 (InVitrogen) by standard cloning methods (Sambrook et al, MOLECULAR CLONING: A LABORATORY MANUAL, THIRD EDITION, 2001), creating the plasmid pTA2.1-hPMS134.
  • the pTA2.1-hPMS134 plasmid was digested with the restriction enzyme EcoRI to release the insert (there are two EcoRI restriction sites in the multiple cloning site of pTA2.1 that flank the insert) and the fragment was end-filled using Klenow fragment and dNTPs.
  • the fragment was gel purified, digested with Ndel, and inserted in pT7-Ea (which had been digested with Ndel and BamHI, end-filledusing Klenow, and phosphatase treated).
  • the new plasmid was designated pT7-Ea-hPMS134.
  • the following strategy similar to that described above to clone human PMSl 34, was used to construct an expression vector for the human related gene PMSR3.
  • the hPMSR3 fragment was amplified by PCR to introduce two restriction sites: an Ndel restriction site at the 5'- end, and an Eco RI site at the 3 '-end of the fragment.
  • the 5 '-oligonucleotide that was used for PCR has the following sequence: 5'-acg cat atg tgt cct tgg egg cct aga-3' (SEQ ID NO: 25) that includes the Ndel restriction site (CAT ATG).
  • the 3 '-oligonucleotide used for PCR has the following sequence: 5 '-gaa ttc tta tta cgt aga ate gag ace gag gag gag agg gtt agg gat agg ctt ace cat gtg tga tgt ttc aga gct-3' (SEQ ID NO:26) that includes an EcoRI site (gaattc) and the V5 epitope to allow for antibody detection.
  • the plasmid that contained human PMSR3 in pBluescript SK (Nicolaides et al.
  • Genomics 30: 195-206 was used as the PCR target with the hPMS2-specific oligonucleotides above. Following 25 cycles of PCR (95°C for 1 minute, 55°C for 1 minute, 72°C for 1.5 minutes for 25 cycles followed by 3 minutes at 72°C). The PCR fragment was purified by gel electrophoresis and cloned into pTA2.1 (InVitrogen) by standard cloning methods (Sambrook et al, MOLECULAR CLONING: A LABORATORY MANUAL, THIRD EDITION, 2001), creating the plasmid pTA2.1-hR3.
  • the pTA2.1-hR3 plasmid was next digested with the restriction enzyme EcoRI to release the insert (there are two EcoRI restriction sites in the multiple cloning site of pTA2.1 that flank the insert) and the fragment was end-filled using Klenow fragment and dNTPs. Then, the fragment was gel purified, digested with Ndel, and inserted in pT7-Ea (which had been digested with Ndel and BamHI, end-filled using Klenow, and phosphatase treated). The new plasmid was designated pT7-Ea-hR3.
  • BL21 cells harbor an additional expression vector for the lysozyme protein, which has been demonstrated to bind to the T7 polymerase in situ; this results in a bacterial strain that has very low levels of T7 polymerase expression.
  • IPTG inducer isopropyl-beta-D-thiogalactopyranoside
  • the cells express high-levels of T7 polymerase due to the IPTG-inducible element that drives expression of the polymerase that is resident within the genome of the BL21 cells (Studier et al. (1991) J. Mol. Biol. 219(1):37- 44).
  • the BL21 cells are chloramphenicol resistant due to the plasmid that expresses lysozyme within the cell.
  • the cells were made competent by incubating the cells in ice cold 50mM CaCl 2 for 20 minutes, followed by concentrating the cells and adding super-coiled plasmid DNA as describe ( Sambrook et al, MOLECULAR CLONING: A LABORATORY MANUAL, THIRD EDITION, Cold Spring Harbor Laboratory Press, 2001).
  • Ampicillin resistant BL21 were selected on LB-agar plates [5% yeast extract, 10% bactotryptone, 5% NaCl, 1.5% bactoagar, pH 7.0 (Difco)] plates containing 25 ⁇ g/ml chloramphenicol and lOO ⁇ g/ml ampicillin. The next day, bacterial colonies were selected and analyzed by restriction endonuclease digestion and sequence analysis for plasmids containing an intact pTACPMS134 or pTAC empty plasmid .
  • the Ndel-Xhol cloning site is flanked by the TACLAC promoter that contains the Lad repressor site followed by a Shine-Dalgarno ribosome-binding site at the 5' flanking region and the T1T2 ribosomal RNA terminator in the 3' flanking region.
  • the TACLAC vector also contains the Lad gene, which is constitutively expressed by the TAC promoter.
  • DH10B bacterial cells containing the pBCSK vector (Stratagene), which constitutively expresses the -galactosidase gene and contains the chloramphenicol resistance marker for selection, were made competent via the CaCl 2 method (Sambrook, et al. MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory Press, 1982). This vector turns bacterial cells blue when grown in the presence of IPTG and X-gal that aids in the detection of bacterial colonies. Competent cells were transfected with the pTAC empty vector or the pTACPMS134 vector following the heat-shock protocol.
  • Transfected cultures were plated onto LB-agar [5% yeast extract, 10% bactotryptone, 5% NaCl, 1.5% bactoagar, pH 7.0 (Difco)] plates containing 25 ⁇ g/ml chloramphenicol and 100 ⁇ g/ml ampicillin. The next day, bacterial colonies were selected and analyzed by restriction endonuclease digestion and sequence analysis for plasmids containing an intact pTACPMS 134 or pTAC empty plasmid.
  • blots were probed with an anti-V5 monoclonal antibody followed by a secondary goat anti-mouse horseradish peroxidase-conjugated antibody. After incubation with the secondary antibody, blots are developed using chemiluminescence (Pierce) and exposed to film to measure PMS134 expression.
  • Table 3 shows an example in which bacterial cells were inoculated at 1 x 10 7 cells/ml and grown for 6 hours in the presence of tetracycline (Tet).
  • Tet tetracycline
  • pT7Ea control culture did not grow in the presence of Tet while pT7PMS134 and pT7PMSR3 cultures resistant to Tet grew to confluence at time 4 hours after inoculation.
  • EXAMPLE 3 Genomic analysis of antibiotic resistant bacteria and target discovery.
  • Linear DNA fragments containing candidate gene sequences were prepared by PCR, incorporating sequences for in vitro transcription and translation in the sense primer.
  • the sense primer contains the leader sequence 5'-tttaatacgactcactatagggagaccaccatggnnn nnn nnn nnn-3' (SEQ ID NO:27) where the series of "n" nuclsotides indicates sequence corresponding to the first 5 codons.
  • the antisense primer consists of nucleotide sequences surrounding and including the natural stop codon of the gene. DNA fragments are PCR amplified using buffers and condions as described (Nicolaides et al. (1995) Genomics 30:195-206).
  • PCR reaction mix Two to five microliters of whole bacteria are added to the PCR reaction mix and reactions are carried out at 95°C for 1 minute for one cycle followed by thirty cycles at 95°C for 30 sec, 52°C for 2 minute and 72°C for 2 minutes. PCR products are then directly added to a rabbiti reticulolysate mixture to carry out transcription-coupled-translation (Promega). The reaction mixtures were supplemented with [ 35 S]-methionine for detection purposes. Translation reactions are incubated for 2 hours. After the reaction is complete, an equal volume of 2X SDS lysis buffer is added to the samples, and the samples are boiled and then loaded onto 12% NuPAGE gels (No vex). Gels are run at 150V, dried and exposed to autoradiography.
  • Products that are smaller than the expected molecular weight of the wild-type protein (as compared to the control samples) are then determined to be mutant and DNA fragments are sequenced to confirm the presence of a frame-shift/nonsense mutation. This approach has been used to identify mutations in bacterial genes that have been previously been reported to produce antibiotic resistance in bacteria.
  • Cisplatin and adriamycin resistance are associated with MutLa and mismatch repair deficiency in an ovarian tumor cell line. J.Biol.Chem. 271:9645-19648.
  • GTBP a 160-kilodalton protein essential for mismatch-binding activity in human cells. Science 268:1912-1914.
  • Msh2p-Msh6p role of ATP hydrolysis and Msh2p-Msh6p subunit interactions in mismatch base pair recognition.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés de production de bactéries résistant aux antibiotiques, qui comporte les étapes consistant à : bloquer dans une bactérie la réparation de mésappariements afin d'obtenir des bactéries hypermutables ; mettre en contact les bactéries avec au moins un antibiotique ; sélectionner les bactéries résistant à l'antibiotique ; et mettre en culture les bactéries résistant à l'antibiotique. L'invention concerne aussi des procédés visant à déterminer les gènes responsables de la résistance aux antibiotiques.
EP01963754A 2001-07-25 2001-07-25 Procedes de production de microbes resistant aux antibiotiques et nouveaux antibiotiques Withdrawn EP1417329A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/023888 WO2003012130A1 (fr) 2001-07-25 2001-07-25 Procedes de production de microbes resistant aux antibiotiques et nouveaux antibiotiques

Publications (2)

Publication Number Publication Date
EP1417329A1 true EP1417329A1 (fr) 2004-05-12
EP1417329A4 EP1417329A4 (fr) 2005-05-11

Family

ID=21742739

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01963754A Withdrawn EP1417329A4 (fr) 2001-07-25 2001-07-25 Procedes de production de microbes resistant aux antibiotiques et nouveaux antibiotiques

Country Status (3)

Country Link
EP (1) EP1417329A4 (fr)
CA (1) CA2455686A1 (fr)
WO (1) WO2003012130A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2506127C (fr) 2002-11-15 2013-07-09 Morphotek, Inc. Methodes de generation d'une quantite elevee d'anticorps a partir d'hybridomes crees par immunisation in vitro
US10760110B2 (en) * 2017-02-24 2020-09-01 KeMyth Biotech Co., Ltd. Antibiotic testing and screening system

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146894A (en) * 1998-04-14 2000-11-14 The Johns Hopkins University Method for generating hypermutable organisms
WO2002054856A1 (fr) * 2001-01-15 2002-07-18 Morphotek Inc. Inhibiteurs chimiques de reparation de desappariements

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY103919A (en) * 1988-03-30 1993-10-30 Kao Corp Mutant resistant to cell membrane synthesis inhibitor and process for preparing the same.
DE19717346C2 (de) * 1997-04-24 1999-05-20 Max Planck Gesellschaft DNA-Sonden, Verfahren und Kit zur Identifizierung Antibiotika-resistenter Bakterienstämme

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146894A (en) * 1998-04-14 2000-11-14 The Johns Hopkins University Method for generating hypermutable organisms
WO2002054856A1 (fr) * 2001-01-15 2002-07-18 Morphotek Inc. Inhibiteurs chimiques de reparation de desappariements

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DRUMMOND ET AL.: "DHFR/MSH3 amplification in methotrexate-resistant cells alters the hMutS alpha /hMutS beta ratio and reduces the efficiency of base-base mismatch repair." PROC. NATL. ACAD. SCI. USA, vol. 94, July 1997 (1997-07), pages 10144-10149, XP002320277 *
DRUMMOND J T ET AL: "CISPLATIN AND ADRIAMYCIN RESISTANCE ARE ASSOCIATED WITH MUTL-ALPHA AND MISMATCH REPAIR DEFICIENCY IN AN OVARIAN TUMOR CELL LINE" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 271, no. 33, 16 August 1996 (1996-08-16), pages 19645-19648, XP002939396 ISSN: 0021-9258 *
PETER KARRAN: "Mechanisms of tolerance to DNA damaging therapeutic drugs" CARCINOGENESIS, vol. 22, no. 12, December 2001 (2001-12), pages 1931-1937, XP002320360 *
See also references of WO03012130A1 *

Also Published As

Publication number Publication date
WO2003012130A1 (fr) 2003-02-13
EP1417329A4 (fr) 2005-05-11
CA2455686A1 (fr) 2003-02-13

Similar Documents

Publication Publication Date Title
Marinus et al. DNA methylation
JP4015193B2 (ja) 反復的選択および組換えにより所望の特徴を有するポリヌクレオチドを作製する方法
WO2018031950A1 (fr) Procédés de génie protéique
KR20180069898A (ko) 핵염기 편집제 및 그의 용도
Uzest et al. Lethality of rep recB and rep recC double mutants of Escherichia coli
Bierne et al. uvrD mutations enhance tandem repeat deletion in the Escherichia coli chromosome via SOS induction of the RecF recombination pathway
JP2003033180A (ja) ランダムフラグメント化および再組立によるｄｎａ変異誘発
EP1268765B1 (fr) Procedes d'obtention de microbes hypermutables
Kouzminova et al. RNase HII saves rnhA mutant Escherichia coli from R-loop-associated chromosomal fragmentation
Kim et al. Directed evolution of RecA variants with enhanced capacity for conjugational recombination
Egan et al. Lambda red-mediated recombineering in the attaching and effacing pathogen Escherichia albertii
WO2015168600A2 (fr) Procédés et appareil pour transformer des cellules naturellement compétentes
US11608570B2 (en) Targeted in situ protein diversification by site directed DNA cleavage and repair
EP1417329A1 (fr) Procedes de production de microbes resistant aux antibiotiques et nouveaux antibiotiques
KR100491810B1 (ko) 무작위단편화및재조립에의한dna돌연변이유발방법
Marra et al. DNA mismatch repair and colon cancer
CN116096887A (zh) 包括改进的向导rna的组合物和方法
JP3526326B2 (ja) 部位特異的変異導入方法
JP4485061B2 (ja) 突然変異誘発方法
US20030068808A1 (en) Methods for generating antibiotic resistant microbes and novel antibiotics
Matera Global mapping of RNA-RNA interactions in\(Salmonella\) via RIL-seq
AU2003248361B2 (en) Methods of making hypermutable cells using PMSR homologs
Graffeuil et al. Polar mutagenesis of polycistronic bacterial transcriptional units using Cas12a
Chaudhari Microbial Genetics
Tsai Interactions among Dam, SeqA and mismatch repair proteins in Escherichia coli

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040209

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050401

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060522